Pieris Pharmaceuticals Inc (NASDAQ:PIRS) Receives $5.50 Consensus Price Target from Analysts

Shares of Pieris Pharmaceuticals Inc (NASDAQ:PIRS) have been given an average rating of “Buy” by the six analysts that are covering the stock, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a hold recommendation, three have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month price target among analysts that have covered the stock in the last year is $5.50.

Several research firms have recently issued reports on PIRS. HC Wainwright reissued a “buy” rating and set a $7.00 target price on shares of Pieris Pharmaceuticals in a research note on Monday, November 11th. William Blair restated a “buy” rating on shares of Pieris Pharmaceuticals in a research report on Monday, November 11th. ValuEngine downgraded Pieris Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Wednesday, November 13th. Finally, Zacks Investment Research raised Pieris Pharmaceuticals from a “hold” rating to a “strong-buy” rating and set a $4.50 target price for the company in a research note on Thursday, November 28th.

In other news, major shareholder Bvf Partners L. P/Il sold 50,000 shares of the business’s stock in a transaction dated Friday, September 6th. The shares were sold at an average price of $4.50, for a total transaction of $225,000.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. 6.59% of the stock is owned by insiders.

Several institutional investors and hedge funds have recently modified their holdings of PIRS. Tower Research Capital LLC TRC increased its holdings in shares of Pieris Pharmaceuticals by 1,074.8% during the 2nd quarter. Tower Research Capital LLC TRC now owns 5,874 shares of the biotechnology company’s stock worth $28,000 after buying an additional 5,374 shares during the last quarter. Lindbrook Capital LLC acquired a new stake in shares of Pieris Pharmaceuticals during the second quarter valued at about $37,000. Clear Harbor Asset Management LLC purchased a new stake in shares of Pieris Pharmaceuticals in the 2nd quarter valued at approximately $47,000. Jane Street Group LLC purchased a new stake in shares of Pieris Pharmaceuticals in the 2nd quarter valued at approximately $47,000. Finally, A.R.T. Advisors LLC acquired a new position in shares of Pieris Pharmaceuticals in the 2nd quarter worth approximately $84,000. Hedge funds and other institutional investors own 51.27% of the company’s stock.

Shares of PIRS traded up $0.02 during mid-day trading on Friday, reaching $3.92. The company had a trading volume of 15,628 shares, compared to its average volume of 720,274. The stock has a market capitalization of $212.77 million, a P/E ratio of -7.81 and a beta of 1.32. Pieris Pharmaceuticals has a 52-week low of $2.39 and a 52-week high of $6.04. The stock has a 50 day moving average of $3.60 and a two-hundred day moving average of $4.27.

Pieris Pharmaceuticals (NASDAQ:PIRS) last announced its quarterly earnings results on Monday, November 11th. The biotechnology company reported ($0.05) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.23) by $0.18. The company had revenue of $15.13 million during the quarter, compared to the consensus estimate of $6.28 million. Pieris Pharmaceuticals had a negative return on equity of 132.02% and a negative net margin of 107.24%. Analysts anticipate that Pieris Pharmaceuticals will post -0.78 earnings per share for the current year.

About Pieris Pharmaceuticals

Pieris Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers and develops anticalin-based drugs in the United States. The company develops anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in blood plasma and other bodily fluids.

Featured Story: Straddles

Receive News & Ratings for Pieris Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pieris Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.